Application of butylphthalide in preparation of medicine for treating dementia with Lewy bodies

Abstract

The invention provides application of butylphthalide or an optical isomer, a prodrug, a deuterated compound, a metabolite, a ring-opening product and a salt thereof in preparation of medicines for preventing and / or treating dementia with Lewy bodies. Researches show that after 2 weeks of intraperitoneal injection of a representative drug butylphthalide, the movement and cognitive competence of a transgenic mouse with alpha-synuclein A53T mutation can be improved, and olfactory disorder can be reversed; immunohistochemical studies find that butylphthalide can increase striatum and nigra TH staining positive cells of a transgenic mouse with alpha-synucleinA53T mutation, and the deposition of alpha-synucleinA53T is reduced; and by adjusting the mitochondrial fusion fission state, maintaining the mitochondrial homeostasis and reducing mitochondrial autophagy, nerve cells are protected, the movement, perception and cognitive impairment of dementia with Lewy bodies is obviously improved, and important clinical application value is achieved.

Description

technical field [0001] The patent belongs to the field of medicine, and specifically relates to the use of butylphthalide in the preparation of medicines for preventing and / or treating dementia with Lewy bodies. Background technique [0002] Dementia with Lewy body (DLB) is a group of neurodegenerative diseases characterized clinically by fluctuating cognitive impairment, vivid visual hallucinations, and spontaneous parkinsonism, and pathologically characterized by neuronal Lewy bodies . Most DLB onset is age-related, so its prevalence increases as human life expectancy increases worldwide. According to research, DLB accounts for 15% to 20% of senile dementia, which is second only to Alzheimer's disease (AD). According to non-population-based studies, the prevalence of DLB ​​in all dementias over the age of 65 ranges from 3.0% to 26.3%, which is similar to the autopsy findings of 15% to 25%. Based on a small number of demographic surveys, the prevalence of DLB ​​is 0.1% t...

AI Technical Summary

Problems solved by technology

But the potential and mechanism of butylphthalide in the treatment of Lewy body dementia have not been reported

Images